Caelum Biosciences
New York, US · Founded 2015 · Delaware corporation
Biotech
Founders & leadership
MS
Michael SpectorExecutive
MG
Martin GoldmanNamed on SEC filing
KW
Kenneth W. CappellNamed on SEC filing
WN
William NatbonyNamed on SEC filing
JP
Jeffrey PaleyNamed on SEC filing
DH
David HorinNamed on SEC filing
Board
LA
Lindsay A. RosenwaldBoard director
MS
Michael S. WeissBoard director
Reported raises · per SEC filings
Form D private placements$9.9M disclosed across 1 round · 2017
▶$9.9MraisedSep 2017 · 167 investors · BiotechnologyRule 506(b)
▶$9.9MraisedSep 2017 · 167 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin GoldmanDirector
- Lindsay A. RosenwaldDirector
- Kenneth W. CappellDirector
- Michael S. WeissDirector
- Michael SpectorExecutive Officer, Director
- William NatbonyDirector
- Jeffrey PaleyDirector
- David HorinExecutive Officer
- Offering amount
- $10M
- Amount sold
- $9.9M
- Sales commissions
- $991.4K
- Placement agents
- National Securities Corporation
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Caelum Biosciences raised?
- Caelum Biosciences has disclosed $9.9M raised across 1 round.
- Where is Caelum Biosciences headquartered?
- Caelum Biosciences is headquartered in New York, US.